2017
DOI: 10.1111/apt.14043
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Ferric carboxymaltose was the most effective intravenous iron formulation, followed by iron sucrose. In addition, ferric carboxymaltose tended to be better tolerated. Thus, nanocolloidal IV iron products exhibit differing therapeutic and safety characteristics and are not interchangeable.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
89
0
6

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
3

Relationship

2
8

Authors

Journals

citations
Cited by 92 publications
(97 citation statements)
references
References 68 publications
2
89
0
6
Order By: Relevance
“…As FCM and novel iron formulations gain traction in patients requiring chronic supplementation due to their ease of use,20 we may see more cases of FGF23-induced hypophosphataemia and associated osteomalacia. Wolf et al 4 demonstrate that the majority of women who receive FCM have transient hypophosphataemia.…”
Section: Discussionmentioning
confidence: 99%
“…As FCM and novel iron formulations gain traction in patients requiring chronic supplementation due to their ease of use,20 we may see more cases of FGF23-induced hypophosphataemia and associated osteomalacia. Wolf et al 4 demonstrate that the majority of women who receive FCM have transient hypophosphataemia.…”
Section: Discussionmentioning
confidence: 99%
“…However, differences in the safety profile of these iron-containing products have been observed both in a systemic review of clinical trials [24] and in a retrospective analysis of clinical data [25]. The recently published systematic network meta-analysis based on five randomised, controlled trials has compared the tolerability of different i.v.…”
Section: Discussionmentioning
confidence: 99%
“…1 In our study, 2 Bayesian Network Meta-Analysis was performed on five randomised controlled trials (1143 patients) to compare the efficacy of different intravenous iron therapies in inflammatory bowel disease (IBD) patients with anaemia. We chose the fixed effects model after evaluating statistical heterogeneity and consistency of trial data, both of which influence the reliability of network…”
mentioning
confidence: 99%